Subspecialties

A new matrix therapy agent may promote corneal healing after epi-off CXL, improving patient comfort and recovery times

Highlights from Laboratoires Théa’s Satellite Education Program, “Ocular Surface: What’s New?” held on October 8, 2015, at the 7th EVER Congress, Nice, France.

What does analysis of the last five years of literature on endophthalmitis tell us about the priorities of the field, and the contributors to it?

Implanting a toric IOL during cataract surgery is great way of dealing with a patient’s corneal astigmatism – but off-axis rotation of the IOL can erode those benefits.

CXL is effective in slowing and halting keratoconus and corneal ectasias – but the thinnest corneas can’t receive it, so we propose a new way of bringing CXL to those that need it most

Here, we recognize a year’s worth of innovation. Apps, IOLs, imagers, lasers, devices and drugs – the latest and greatest are all here. But which one came out on top this year?

Placental growth factor inhibitors might show efficacy in treating dry AMD as well as wet. Might aflibercept be repurposed?

Big data EMR mining (and some basic research) identifies a 50-year old drug that appears to protect against AMD development

A new tissue culture model of the retinal pigment epithelium may allow researchers to better understand the impacts of new interventions on the adult human retina

George discusses his current research focus in the field of cataract refractive surgery.